Drug Trial Radar · NCT07686120
A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
286
Planned (sponsor's estimate)
Start
Sep 17, 2026
Primary completion
Feb 9, 2028
Study completion Feb 9, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Tigermed Consulting Co., Ltd
- First posted
- Jul 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase IIIb, multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of baxdrostat 2mg versus placebo, administered QD orally, on the reduction of ambulatory 24-hour average SBP in participants with uHTN. Consenting participants will be screened within 4 weeks and will subsequently enter a 4-week run-in period with placebo. Thereafter, participants will be randomised in a 1:1 ratio to receive one of the following 2 treatments QD, during a 12-week double-blind treatment period: baxdrostat 2mg Placebo The randomisation will be stratified by mean ambulatory SBP at baseline (\<140 mmHg, ≥140 mmHg) and the number of background antihypertensive medication classes (2, ≥3) at baseline. During the 12-week double-blind treatment period, participants should remain on their background antihypertensive medication. Doses of background medications should not be changed during this period unless participants experience SBP \< 100 mmHg with symptoms of hypotension. Rescue therapy is permitted if the SBP or DBP exceeds 170 or 105 mmHg, respectively. The choice of rescue therapy is based on the Investigator's best clinical judgement; however, the use of potassium-sparing diuretics and MRAs are prohibited.After completing the 12 weeks double-blind treatment period participants will complete a 2-week safety follow-up period. The total duration of study participation will be of approximately 22 weeks.
Conditions
- Uncontrolled Hypertension
Interventions
baxdrostat 2mgDrug
baxdrostat 2mg tablet administered orally, once daily (QD).
Placebo 2mgDrug
Placebo 2mg tablet administered orally, once daily (QD).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in ambulatory 24-hour average Systolic blood pressure(SBP) at Week 12Time frame: Week12
Locations
51 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Beijing, China · Recruiting
Research Site
Beijing, China · Not yet recruiting
Research Site
Beijing, China · Not yet recruiting
Research Site
Beijing, China · Not yet recruiting
Research Site
Bengbu, China · Not yet recruiting
Research Site
Changchun, China · Not yet recruiting
Research Site
Changsha, China · Not yet recruiting
Research Site
Chengdu, China · Not yet recruiting
Research Site
Chengdu, China · Not yet recruiting
Research Site
Chongqing, China · Not yet recruiting
Research Site
Foshan, China · Not yet recruiting
Research Site
Fuzhou, China · Not yet recruiting
Research Site
Fuzhou, China · Not yet recruiting
Research Site
Guangzhou, China · Not yet recruiting
Research Site
Guangzhou, China · Not yet recruiting
Research Site
Guangzhou, China · Not yet recruiting
Research Site
Haikou, China · Not yet recruiting
Research Site
Hangzhou, China · Not yet recruiting
Research Site
Jinan, China · Not yet recruiting
Research Site
Jinan, China · Not yet recruiting
Research Site
Kunming, China · Not yet recruiting
Research Site
Lanzhou, China · Not yet recruiting
Research Site
Lu'an, China · Not yet recruiting
Research Site
Nanchang, China · Not yet recruiting
Research Site
Nanjing, China · Not yet recruiting
Research Site
Nanjing, China · Not yet recruiting
Research Site
Nanjing, China · Not yet recruiting
Research Site
Nanning, China · Not yet recruiting
Research Site
Ningbo, China · Not yet recruiting
Research Site
Qingdao, China · Not yet recruiting
Research Site
Shanghai, China · Not yet recruiting
Research Site
Shanghai, China · Not yet recruiting
Research Site
Shanghai, China · Not yet recruiting
Research Site
Shanghai, China · Not yet recruiting
Research Site
Shanghai, China · Not yet recruiting
Research Site
Shantou, China · Not yet recruiting
Research Site
Shenyang, China · Not yet recruiting
Research Site
Shenzhen, China · Not yet recruiting
Research Site
Shijiazhuang, China · Not yet recruiting
Research Site
Suzhou, China · Not yet recruiting
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.